Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE-3: MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Cell Carcinoma
NCT07469241Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07469241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469241.